STOCK TITAN

Royalty Pharma CFO reports 257,122 shares sold indirectly

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Royalty Pharma plc’s executive vice president and chief financial officer, Terrance P. Coyne, reported indirect sales of 257,122 Class A ordinary shares through entities on November 16 and November 17, 2026. Reported weighted-average prices were $68.8680–$68.8681 per share on November 16 and $68.3047 per share on November 17. The sales were made under a Rule 10b5-1 plan adopted August 6, 2026. TPC RP EPA1 LLC reported zero shares after selling 7,122 shares.

Insider Coyne Terrance P.
Role EVP & CFO
Sold 257,122 shs ($17.69M)
Type Security Shares Price Value
Sale Class A Ordinary Shares F1, F3 14,751 $68.3047 $1.01M
Sale Class A Ordinary Shares F1, F3 9,835 $68.3047 $672K
Sale Class A Ordinary Shares F1, F2 135,249 $68.8681 $9.31M
Sale Class A Ordinary Shares F1, F2 90,165 $68.868 $6.21M
Sale Class A Ordinary Shares F1, F4 7,122 $68.868 $490K
Holding Class A Ordinary Shares -- -- --
Holding Class A Ordinary Shares -- -- --
Holding Class A Ordinary Shares -- -- --
Holding Class A Ordinary Shares -- -- --
Holdings After Transaction: Class A Ordinary Shares — 0 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 0 shares (Indirect, By TPC RP, LLC); Class A Ordinary Shares — 0 shares (Indirect, By TPC RP EPA1 LLC); Class A Ordinary Shares — 24,170 shares (Indirect, By Spouse's IRA); Class A Ordinary Shares — 23,270 shares (Indirect, By IRA); Class A Ordinary Shares — 1,500 shares (Direct); Class A Ordinary Shares — 1,450 shares (Indirect, By Spouse)
Footnotes (4)
  1. F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 6, 2026.
  2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.35 to $69.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.79 to $68.75 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.36 to $69.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Class A ordinary shares sold 257,122 shares Five indirect sales on November 16 and November 17, 2026
Shares sold by TPC RP 2021, LLC 135,249 shares November 16, 2026; weighted-average price $68.8681 per share
Shares sold by TPC RP, LLC 90,165 shares November 16, 2026; weighted-average price $68.8680 per share
Shares sold by TPC RP EPA1 LLC 7,122 shares November 16, 2026; weighted-average price $68.8680 per share; reported zero shares afterward
Shares sold by TPC RP 2021, LLC 14,751 shares November 17, 2026; weighted-average price $68.3047 per share
Shares sold by TPC RP, LLC 9,835 shares November 17, 2026; weighted-average price $68.3047 per share
Reported remaining shares in TPC RP EPA1 LLC 0 shares After the November 16, 2026 sale
Rule 10b5-1 plan regulatory
"sales made under a Rule 10b5-1 plan adopted August 6, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RPRX shares did Terrance P. Coyne’s entities sell?

The indirect sales totaled 257,122 Class A ordinary shares across November 16 and November 17, 2026. Reported weighted-average prices were $68.8680–$68.8681 per share on November 16 and $68.3047 per share on November 17.

How many shares remained in TPC RP EPA1 LLC after the RPRX sale?

The entity reported zero Class A ordinary shares after its sale of 7,122 shares on November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coyne Terrance P.

(Last)(First)(Middle)
C/O ROYALTY PHARMA PLC
110 EAST 59TH STREET

(Street)
NEW YORK NEW YORK 10022

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Shares11/16/2026S(1)135,249D(2)$68.868114,751IBy TPC RP 2021, LLC
Class A Ordinary Shares11/17/2026S(1)14,751D(3)$68.30470IBy TPC RP 2021, LLC
Class A Ordinary Shares11/16/2026S(1)90,165D(2)$68.8689,835IBy TPC RP, LLC
Class A Ordinary Shares11/17/2026S(1)9,835D(3)$68.30470IBy TPC RP, LLC
Class A Ordinary Shares11/16/2026S(1)7,122D(4)$68.8680IBy TPC RP EPA1 LLC
Class A Ordinary Shares24,170IBy Spouse's IRA
Class A Ordinary Shares23,270IBy IRA
Class A Ordinary Shares1,500D
Class A Ordinary Shares1,450IBy Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 6, 2026.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.35 to $69.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.79 to $68.75 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.36 to $69.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,198,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,788,777 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.
/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading